Serum basic fibroblast growth factor and interleukin-1β predict the effect of first-line chemotherapy in patients with advanced gastric cancer

Li Zheng; Li-Hong Gan; Ling Yao; Bin Li; Ya-Qin Huang; Fu-Bao Zhang; Meng-Qi Kuang; Nian Fang

doi:10.12998/wjcc.v11.i26.6083

Serum basic fibroblast growth factor and interleukin-1β predict the effect of first-line chemotherapy in patients with advanced gastric cancer

World J Clin Cases. 2023 Sep 16;11(26):6083-6090. doi: 10.12998/wjcc.v11.i26.6083.

Authors

Li Zheng¹, Li-Hong Gan¹, Ling Yao¹, Bin Li¹, Ya-Qin Huang¹, Fu-Bao Zhang², Meng-Qi Kuang¹, Nian Fang³

Affiliations

¹ Department of Gastroenterology, The First Hospital of Nanchang, Nanchang 330008, Jiangxi Province, China.
² Department of Stomatology, The First Hospital of Nanchang, Nanchang 330008, Jiangxi Province, China.
³ Department of Gastroenterology, The First Hospital of Nanchang, Nanchang 330008, Jiangxi Province, China. zl13870673345@163.com.

Abstract

Background: The incidence and mortality rates of gastric cancer in China are the second-highest in the world, and most patients with gastric cancer lose their chance of surgery by the time of their diagnosis.

Aim: To explore the predictive potential of serum basic fibroblast growth factor and interleukin-1β levels for the effect of first-line chemotherapy in patients with advanced gastric cancer.

Methods: From the gastric cancer patients admitted to our hospital from May 2019 to April 2023, 84 patients were selected and randomly and equally assigned to the experimental or control group. The FLOT group received the FLOT chemotherapy regimen (composed of oxaliplatin + calcium folinate + fluorouracil + paclitaxel), while the SOX group received the SOX chemotherapy regimen (composed of oxaliplatin + tiga capsules). The clinical efficacy, tumor marker levels, adverse reactions, and survival rates of the two groups were compared 7 days after the end of the relevant treatments.

Results: The target effective rate of the FLOT group was 54.76%, which was much higher than that of the SOX group (33.33%; P < 0.05). After treatment, both the groups demonstrated lower levels of cancer antigen (CEA), carbohydrate antigen 199 (CA199), and peptide tissue antigen (TPS). For several patients before treatment (P < 0.05). Third and fourth grades. In terms of adverse reactions, the level of white blood cells in both the groups was lower. Moreover, the incidence of hand-foot skin reactions in these two study groups was lower (P < 0.05), while those of peripheral neuritis, vomiting, diarrhea, and abnormal liver function were significant (P < 0.05). No statistically significant difference was noted between the two groups (P < 0.05). The 1-year survival rate was higher in the FLOT group (P < 0.05).

Conclusion: The FLOT regimen was effective in reducing the serum CEA, CA199, and TPS levels as well as in improving the 1-year survival rate of patients with good tolerability, making it worthy of clinical promotion and application.

Keywords: Advanced gastric cancer; FLOT regimen; First-line chemotherapy; SOX regimen; Tissue peptide-specific antigen.